benzyl-alpha-n-acetylgalactosamine has been researched along with Allergic Encephalomyelitis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arikawa, T; Hirashima, M; Kadowaki, T; Niki, T; Nishi, N; Oomizu, S; Ueno, M; Yamauchi, A | 1 |
1 other study(ies) available for benzyl-alpha-n-acetylgalactosamine and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Galectin-9 suppresses Th17 cell development in an IL-2-dependent but Tim-3-independent manner.
Topics: Acetylgalactosamine; Animals; Benzyl Compounds; Cells, Cultured; Encephalomyelitis, Autoimmune, Experimental; Female; Flow Cytometry; Forkhead Transcription Factors; Galectins; Hepatitis A Virus Cellular Receptor 2; Interleukin-17; Interleukin-2; Interleukin-2 Receptor alpha Subunit; Interleukin-6; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptors, Virus; T-Lymphocytes, Regulatory; Th17 Cells; Transforming Growth Factor beta1 | 2012 |